B. Riley Financial, Inc. declined 1.20% in intraday trading. The company raised the price target on Verastem, Inc. to $16 from $13, and initiated coverage on Actuate Therapeutics, Inc. with a buy rating. These actions indicate a positive outlook on the biopharmaceutical sector, which may have influenced the stock's movement.
Comments
No comments yet